PubMed Health⌕ Search

PubMed · 12049973

Accelerated dissolution testing for improved quality assurance.

Abstract

In pharmaceutical production of controlled release tablets and capsules, a rapid and automated at-line dissolution test for quality assurance of semi-products is advantageous. For effective control of the production, the analysis should not take more than about an hour, without loss of correlation to the ordinary (USP) dissolution test of the final product. For almost a decade, the ACDRA apparatus (ACcelerated Dissolution Rate Analysis) have been used for this purpose at AstraZeneca Tablet Production Sweden (TPS). In this paper, we give examples on different ways to accelerate the dissolution process. We use the USP dissolution calibrator tablets of salicylic acid (non-disintegrating type) to illustrate the strategy. We investigate the accelerated dissolution of the dissolution calibrator tablets, and show how it can be correlated with the dissolution in the ordinary USP-II equipment. The dissolution process was accelerated by variation of temperature, solvent and stirring. For example, we show that by increasing the temperature to 70 degrees C, changing the solvent to water, and increasing the stirring, it is possible to accelerate the dissolution by a factor of 5, without any loss of correlation to the dissolution process in the ordinary test.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Per Ola Quist, Göran Ostling. 2002-06-15. Accelerated dissolution testing for improved quality assurance.. https://doi.org/10.1016/s0731-7085(02)00048-1

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma.

A simple, rapid method of determining the ibuprofen concentration in small volumes of human plasma (50 microl) by HPLC was developed. The sample was prepared for injection using a solid-phase extraction method, with naproxen as the internal standard. A 96-well extraction plate was used, easing sample preparation and allowing the simultaneous extraction of multiple plasma samples directly into the HPLC injection vials. Samples were stable at room temperature for at least 48 h prior to injection. The HPLC method used an ultraviolet detector with a 5-min run time and measured concentrations across the range typically seen with the clinical use of this drug. The calibration curve was linear across the concentration range of 0.78-100 microg/ml with a limit of quantitation (LOQ) of 1.56 microg/ml. The coefficient of variation for intra-day and inter-day precision was 6% or less with accuracies within 2% of the nominal values for low (4.5 microg/ml), medium (40 microg/ml) and high (85 microg/ml) ibuprofen concentrations. For ibuprofen concentrations at the LOQ, the intra-day and inter-day precision and accuracy were within 10 and 15%, respectively. Recovery was 87% or greater for ibuprofen. This method was used to analyze plasma samples for unknown ibuprofen concentrations in bioequivalence and limited food effect studies of different formulations of ibuprofen. Thus, this method has been fully validated and used in the analysis of unknown plasma samples for ibuprofen.

Anti-Inflammatory Agents, Non-Steroidal↗

The double-edged sword of COX-2 selective NSAIDs.

The launch of the cyclooxygenase-2 (COX-2) selective NSAIDs was based on 2 hypotheses: (1) the major adverse effects limiting the usefulness of nonselective NSAIDs are gastrointestinal in nature and (2) COX-2 selective NSAIDs are associated with fewer gastrointestinal adverse effects than nonselective NSAIDs. At the time of the launch, neither of these hypotheses had been proven and, as documented in this review, both remain uncertain. The increased incidence of total and nongastrointestinal serious adverse events, with the COX-2 selective NSAIDs as compared with nonselective NSAIDs, in the Celecoxib Long-term Arthritis Safety Study (CLASS) and the Vioxx Gastrointestinal Outcomes Research (VIGOR) study remains a major concern. The increased morbidity associated with the COX-2 selective NSAIDs may be a manifestation of the COX-2 selectivity of rofecoxib and celecoxib or the supramaximal doses of these drugs used in the trials. Proof that the increased harm was not caused by the COX-2 selectivity of the drugs depends on demonstration in a randomized controlled trial that COX-2 selective NSAIDs at usual doses are as effective as nonselective NSAIDs and cause fewer gastrointestinal serious adverse events without increasing the incidence of total nongastrointestinal serious adverse events.

Anti-Inflammatory Agents, Non-Steroidal↗